Atossa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2011 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2011 - 2019
Net Income	-28.72	-25.5	-30.09	-26.96	-20.61	-17.83	Upgrade
Depreciation & Amortization	0.02	0.02	0.02	0.01	0.02	0.05	Upgrade
Stock-Based Compensation	2.88	2.29	4.62	6.79	5.27	3.02	Upgrade
Other Adjustments	-	1.72	2.99	0	-	3.3	Upgrade
Changes in Accounts Payable	0.95	-0.13	-2.16	1.25	0.13	1.3	Upgrade
Changes in Accrued Expenses	0.41	0.15	0.04	1.2	0.33	0.08	Upgrade
Changes in Other Operating Activities	-2.27	0.42	3.64	-3.04	-1.62	-1.49	Upgrade
Operating Cash Flow	-25.02	-21.03	-20.94	-20.76	-16.47	-11.57	Upgrade
Capital Expenditures	-	-0.02	-0.01	-0.03	-0.01	-0.01	Upgrade
Purchases of Investments	-	-	-	-4.7	-	-	Upgrade
Investing Cash Flow	-	-0.02	-0.01	-4.73	-0.01	-0.01	Upgrade
Issuance of Common Stock	-	3.67	-	-	113.88	33.62	Upgrade
Repurchase of Common Stock	-	-	-1.48	-	-0.57	-0.01	Upgrade
Net Common Stock Issued (Repurchased)	-	3.67	-1.48	-	113.3	33.61	Upgrade
Issuance of Preferred Stock	-	-	-	-	-	4.95	Upgrade
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	4.95	Upgrade
Financing Cash Flow	-	3.67	-1.48	-	113.3	38.55	Upgrade
Net Cash Flow	-21.67	-17.38	-22.43	-25.49	96.82	26.97	Upgrade
Beginning Cash & Cash Equivalents	79.64	88.57	111	136.49	39.66	12.69	Upgrade
Ending Cash & Cash Equivalents	57.97	71.19	88.57	111	136.49	39.66	Upgrade
Free Cash Flow	-25.02	-21.05	-20.96	-20.79	-16.48	-11.58	Upgrade
Free Cash Flow Per Share	-0.20	-0.17	-0.17	-0.16	-0.14	-1.02	Upgrade
Levered Free Cash Flow	-29.61	-25.06	-28.57	-27.58	-21.75	-17.9	Upgrade
Unlevered Free Cash Flow	-30.89	-27.18	-29.85	-28.31	-21.66	-14.68	Upgrade

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.